ACAD ACADIA Pharmaceuticals Inc.

NASDAQ
$21.23

ACADIA Pharmaceuticals Inc. (ACAD) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is $0.26 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.4% since its last earnings release on November 4, 2026.

ACADIA Pharmaceuticals Beat Consensus Estimates, Narrows Guidance
Wednesday, November 4, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs $0.26
Rev est $364.65M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $21.24

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the business of development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.